The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients
Abstract
Objective: This study aimed to investigate the feasibility and accuracy of non-radioactive TLN biopsy and TAD in routine clinical practice. Background Data: TAD involves TLN biopsy (TLNB) and sentinel lymph node biopsy and was recently introduced as a new standard for less invasive axillary staging in BC patients undergoing neoadjuvant systemic therapy (NST); however, clinical evidence is limited. Methods: The SenTa study is a prospective registry study conducted at 50 centers. Patients with invasive BC who nderwent clip insertion into the most suspicious axillary lymph node were eligible. Axillary surgery was performed with or without sentinel lymph node biopsy, TLNB, and/or axillary lymph node dissection (ALND). Main endpoints were the detection rate and FNR of TLNB and TAD after NST. Results: Between 2017 and 2018, 548 consecutive BC patients underwent clip placement into biopsy-confirmed positive lymph nodes. After NST (n = 473), the clipped TLN was intraoperatively resected in 329 of 423 patients [77.8%, 95% confidence interval (CI): 74.0–82.0]. TAD was successful in 199 of 229 patients (detection rate: 86.9%, 95% CI: 81.8–91.0), the SLN and TLN were identical in 129 patient (64.8%). FNRs were 7.2% (8 of 111, 95% CI: 3.1–13.6) for TLNB followed by ALND (n = 203) and 4.3% (2 of 46, 95% CI: 0.5–14.8) for TAD followed by ALND (n = 77). Conclusions: The SenTa study demonstrates the feasibility of TAD in a real-world cohort of BC patients. Our findings are of great importance for de-escalation of surgical strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Cited by
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Breast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · Cancer Communications · doi:10.1002/cac2.12358 · Cited by 407
Metadata
- Authors
- Kuemmel, S., Heil, J., Rueland, A., Seiberling, C., Harrach, H., Schindowski, D., Lubitz, J., Hellerhoff, K., Ankel, C., Graßhoff, S.-T., Deuschle, P., Hanf, V., Belke, K., Dall, P., Dorn, J., Kaltenecker, G., Kuehn, T., Beckmann, U., Potenberg, J., Blohmer, J.-U., Kostara, A., Breit, E., Holtschmidt, J., Traut, E., & Reinisch, M.
- Venue
- Annals of Surgery
- Published
- 2020-11-04
- Volume
- 276
- Issue
- 5
- Pages
- e553-e562
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W3096479038
- Cited by
- 181
- References
- 1
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. https://app.cochat.ai/papers/10.1097/sla.0000000000004572
- The paper
- Kuemmel, S., Heil, J., Rueland, A., Seiberling, C., Harrach, H., Schindowski, D., Lubitz, J., Hellerhoff, K., Ankel, C., Graßhoff, S.-T., Deuschle, P., Hanf, V., Belke, K., Dall, P., Dorn, J., Kaltenecker, G., Kuehn, T., Beckmann, U., Potenberg, J., . . . Reinisch, M. (2022). A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. Annals of Surgery. https://doi.org/10.1097/sla.0000000000004572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.